GlassScriptPhysician profile
Edward Spencer
NPI 1548355902
$897.52
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $154 · 2021: $132 · 2022: $174 · 2023: $134 · 2024: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.54 | 2019-2024 | |
| Lilly USA, LLC | $134.50 | 2019-2024 | Mounjaro, Trulicity |
| Allergan, INC. | $112.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $112.12 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $73.21 | 2019-2024 | Proclaim |
| Pfizer INC. | $58.71 | 2024 | |
| Abbvie INC. | $56.65 | 2021-2022 | |
| Medtronic, INC. | $34.48 | 2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $31.23 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.56 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $16.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2024 | Jardiance |
| Amgen INC. | $14.45 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.